Alan Lader
Chief Tech/Sci/R&D Officer at CITIUS PHARMACEUTICALS, INC.
Profile
Alan Lader is currently the SVP, Head-Clinical Operations & Quality Assurance at Citius Pharmaceuticals, Inc. Previously, he worked as the Director-Clinical Operations at Ischemix, Inc. Lader received his undergraduate degree from Syracuse University, his graduate degree from Rensselaer Polytechnic Institute, and his doctorate from the University of South Carolina School of Medicine.
Alan Lader active positions
| Companies | Position | Start |
|---|---|---|
| CITIUS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2016-02-29 |
Former positions of Alan Lader
| Companies | Position | End |
|---|---|---|
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Corporate Officer/Principal | - |
Training of Alan Lader
| University of South Carolina School of Medicine | Doctorate Degree |
| Rensselaer Polytechnic Institute | Graduate Degree |
| Syracuse University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CITIUS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
- Stock Market
- Insiders
- Alan Lader
